Premium
Narrow Band Imaging‐guided resection of oral cavity cancer decreases local recurrence and increases survival
Author(s) -
Farah CS
Publication year - 2018
Publication title -
oral diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.953
H-Index - 87
eISSN - 1601-0825
pISSN - 1354-523X
DOI - 10.1111/odi.12745
Subject(s) - medicine , basal cell , surgery , cancer , resection
Purpose Overall local recurrence of oral squamous cell carcinoma ( OSCC ) is estimated at 20%. Incomplete primary tumour excision contributes to localised postsurgical recurrence of OSCC . The purpose of this study was to report on patient outcomes following resection of OSCC using Narrow Band Imaging ( NBI ). Materials and Methods Patients with OSCC requiring resection were visualised under conventional white light ( WL ) then NBI using an Olympus NBI ENF ‐ VQ nasendoscope with CLV ‐180 light source and processor (Olympus Medical Systems, Tokyo, Japan). OSCC tissue was resected to the NBI ‐defined surgical margins, and patients followed for a minimum of 5 years postsurgery to assess local recurrence rate ( LRR ) and disease‐free survival ( DFS ). Results Of the 20 patients recruited for this study, one patient (5%) declined follow‐up. At the latest follow‐up period (up to 7 years postsurgery), 14 of 19 patients (73.68%) were alive with no recurrence. Two patients (10.53%) had died from metastatic disease with no local recurrence, one patient (5.26%) had died from disease with local recurrence, and two patients (10.53%) had died disease‐free from other causes. In total, 16 of 19 patients (84.21%) who were followed for a minimum of 5 years were still alive and had not developed local recurrence. Only one patient developed local recurrence. Five‐year DFS was 84.21% and LRR was 5.26%. Conclusion Resection to NBI ‐defined margins improves survival rates and decreases recurrence rates of OSCC compared to traditional methods and should be adopted as the new gold standard for determining mucosal surgical margins for treatment of oral cavity cancer. These promising results have set the scene for a multicentred randomised controlled trial comparing NBI to WL currently underway.